Advanced search
Publication Cover
Human Vaccines & Immunotherapeutics Volume 9, 2013 - Issue 9
Submit an article Journal homepage
1,127
Views
18
CrossRef citations to date
0
Altmetric
Research Paper

Feasibility of reducing rabies immunoglobulin dosage for passive immunization against rabies: Results of In vitro and In vivo studies

Shampur Narayan Madhusudana Department of Neurovirology; National Institute of Mental Health & Neurosciences (NIMHANS); Bangalore, IndiaCorrespondence[email protected]
,
Belludi Yajaman Ashwin Department of Neurovirology; National Institute of Mental Health & Neurosciences (NIMHANS); Bangalore, India
&
Sampada Sudarshan Department of Neurovirology; National Institute of Mental Health & Neurosciences (NIMHANS); Bangalore, India
Pages 1914-1917 | Received 04 May 2013, Accepted 17 Jun 2013, Published online: 21 Jun 2013

References

  • World Health Organzation. Expert consultation on rabies. First report. Tech Rep Ser 931, Geneva, WHO, 2005.
  • Habel K. Seropprophylaxis in experimental rabies. Public Health Rep 1945; 60:545 - 60; http://dx.doi.org/10.2307/4585257; PMID: 19316026
  • Koprowski H, Van Der Scheer J, Black J. Use of hyperimmune anti-rabies serum concentrates in experimental rabies. Am J Med 1950; 8:412 - 20; http://dx.doi.org/10.1016/0002-9343(50)90224-5; PMID: 15410721
  • Atanasiu P, Bahmanyar M, Balatazard M. Rabies neutralizing antibody response to different schedules of serum and vaccine inoculation in non exposed persons. Bull World Health Organ 1955; 13:747 - 51; PMID: 13284556
  • World Health Organization. Expert committee on rabies, 6th report. Tech Rep Ser 523, Geneva, WHO, 1973.
  • World Health Organization. Expert committee on rabies 7th report. Tech Rep Ser 709 WHO, Geneva, 1984.
  • World Health Organization. Expert committee on rabies 8th report. Tech Rep Ser 824 Geneva, WHO, 1992.
  • Quiambao BP, Dy-Tioco HZ, Dizon RM, Crisostomo ME, Teuwen DE. Rabies post-exposure prophylaxis with purified equine rabies immunoglobulin: one-year follow-up of patients with laboratory-confirmed category III rabies exposure in the Philippines. Vaccine 2009; 27:7162 - 6; http://dx.doi.org/10.1016/j.vaccine.2009.09.036; PMID: 19925947
  • Müller T, Dietzschold B, Ertl H, Fooks AR, Freuling C, Fehlner-Gardiner C, et al. Development of a mouse monoclonal antibody cocktail for post-exposure rabies prophylaxis in humans. PLoS Negl Trop Dis 2009; 3:e542; http://dx.doi.org/10.1371/journal.pntd.0000542; PMID: 19888334
  • Bakker AB, Python C, Kissling CJ, Pandya P, Marissen WE, Brink MF, et al. First administration to humans of a monoclonal antibody cocktail against rabies virus: safety, tolerability, and neutralizing activity. Vaccine 2008; 26:5922 - 7; http://dx.doi.org/10.1016/j.vaccine.2008.08.050; PMID: 18804136
  • Gogtay N, Thatte U, Kshirsagar N, Leav B, Molrine D, Cheslock P, et al, SII RMab author group. Safety and pharmacokinetics of a human monoclonal antibody to rabies virus: a randomized, dose-escalation phase 1 study in adults. Vaccine 2012; 30:7315 - 20; http://dx.doi.org/10.1016/j.vaccine.2012.09.027; PMID: 23010601
  • Muhamuda K, Madhusudana SN, Ravi V. Use of neutralizing murine monoclonal antibodies to rabies glycoprotein in passive immunotherapy against rabies. Hum Vaccin 2007; 3:192 - 5; http://dx.doi.org/10.4161/hv.3.5.4386; PMID: 17637573
  • Hemachudha T, Mitrabhakdi E, Wilde H, Vejabhuti A, Siripataravanit S, Kingnate D. Additional reports of failure to respond to treatment after rabies exposure in Thailand. Clin Infect Dis 1999; 28:143 - 4; http://dx.doi.org/10.1086/517179; PMID: 10028088
  • Sudarshan MK, Madhusudana SN, Mahendra BJ, Rao NS, Ashwath Narayana DH, Abdul Rahman S, et al. Assessing the burden of human rabies in India: results of a national multi-center epidemiological survey. Int J Infect Dis 2007; 11:29 - 35; http://dx.doi.org/10.1016/j.ijid.2005.10.007; PMID: 16678463
  • Fang LX, Ping F, Ping Y, Hui BG, Yan YX. Socioeconomic status is a critical risk factor for human rabies post-exposure prophylaxis. [d] Vaccine 2010; 28:6847 - 51; http://dx.doi.org/10.1016/j.vaccine.2010.08.034; PMID: 20723628
  • Wilde H, Chutivongse S. Equine rabies immune globulin: a product with an undeserved poor reputation. Am J Trop Med Hyg 1990; 42:175 - 8; PMID: 2316787
  • Archer BG, Dierks RE. Effects of homologous or heterologous antiserum on neutralizing-antibody response to rabies vaccine. Bull World Health Organ 1968; 39:407 - 17; PMID: 5303907
  • World Health Organization. Human and dog rabies prevention and control. Report of the WHO/Bill Gates Foundation Consultation. 7-9 October 2009, Annecy, France WHO/HTM/NTD/NZD/2010.1.
  • Fekadu M, Shaddock JH, Baer GM. Excretion of rabies virus in the saliva of dogs. J Infect Dis 1982; 145:715 - 9; http://dx.doi.org/10.1093/infdis/145.2.715; PMID: 7077094
  • Vaughn JB Jr., Gerhardt P, Newell KW. Excretion of street rabies virus in the saliva of dogs. JAMA 1965; 193:363 - 8; http://dx.doi.org/10.1001/jama.1965.03090050039010; PMID: 14313891

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.